CytomX Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

CytomX Therapeutics

08/11/2022 22:02

* CytomX Therapeutics Inc  CTMX.OQ  reported a quarterly
adjusted
loss of 35 cents​​ per share for the quarter ended in September.
The mean expectation of nine analysts for the quarter was for a
loss of 31 cents per share.
    * Revenue fell 3.8% to $16.92 million from a year ago;
analysts
expected $18.15 million. 
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * CytomX Therapeutics Inc shares had fallen by 13.8% this
quarter and lost 71.1% so far this year.
    * The company reported a quarterly loss of $23.3 million.
    * Wall Street's median 12-month price target for CytomX
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 10:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.31          -0.35          Missed
 Jun. 30 2022      -0.36          -0.37          Missed
 Mar. 31 2022      -0.36          -0.37          Missed
 Dec. 31 2021      -0.28          -0.40          Missed